Organization | Fennec Pharma

Fennec Pharma Report issue

For profit Phase 1 Phase 2

Founded: Raleigh NC United States (1996)

Status: No NME R&D (1996)

Organization Overview

First Clinical Trial

2005

NCT00265057

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Alternative names

Fennec Pharma

Active Ingredients

Drugs in Phase 2 Trials (7)

adh-1 (6 trials)

adh300004 (3 trials)

capecitabine (xeloda) (2 trials)

eniluracil (1 trial)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

melphalan (alkeran) (1 trial)

Drugs in Phase 1 Trials (4)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

docetaxel (taxotere) (1 trial)

gemcitabine (gemzar) (1 trial)

Drugs in Other Trials (1)

sodium thiosulfate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 1)

Biliary Tract Neoplasms (Phase 1)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Cholangiocarcinoma (Phase 1)

Colorectal Neoplasms (Phase 1)

Gallbladder Neoplasms (Phase 1)

Klatskin Tumor (Phase 1)

Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 11
# of Trial APIs: 12